PF 6342674

Drug Profile

PF 6342674

Alternative Names: PF-06342674; PF-6342674; RN-168

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antibodies
  • Mechanism of Action Interleukin 17 receptor antagonists; Interleukin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 1 diabetes mellitus
  • Discontinued Multiple sclerosis

Most Recent Events

  • 01 Sep 2016 Pfizer completes a phase I trial in Type-1 diabetes mellitus in USA (NCT02038764)
  • 02 Aug 2016 PF 6342674 is still in phase I trials for Type-1 diabetes mellitus in USA (Pfizer pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top